New test helps evaluate cancer drug's merit

July 9, 2012

(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.

The KRAS RGQ PCR kit checks for the presence of a certain mutation in the KRAS gene. About 40 percent of people with colon cancer are thought to have the mutation, which leaves Erbitux ineffective. The test is for people whose colorectal cancer has spread to other parts of the body, the FDA said in a news release.

The says more than 141,000 new cases of colon cancer were diagnosed last year in the United States, and nearly 50,000 people died of the disease.

Erbitux (cetuximab), co-marketed by Bristol-Myers Squibb and Eli Lilly, was first approved as a treatment in 2004.

The new diagnostic was developed by Qiagen Manchester Ltd., based in Manchester, England.

Explore further: Researchers link genetic marker to rectal cancer treatment

More information: Visit the FDA to learn more about this approval.


Related Stories

Researchers link genetic marker to rectal cancer treatment

July 6, 2011

A team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can ...

Too many americans skipping colon cancer screening

March 2, 2012

(HealthDay) -- Approximately one in three U.S. adults between the ages of 50 and 75 who should be screened for colorectal cancer have not been, according to the American Society for Gastrointestinal Endoscopy.

Merck KGaA suffers setback on cancer drug

July 5, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.